However, further studies are required to determine the benefit of PARPi outside of the maintenance setting, and targeting of altered HRR genes other than BRCA1/2 should be evaluated in a wide range of cancer subtypes beyond PDAC. The gene discussed is BRCA1; the disease is cancer.